psycho-pharma schreef:
GTC BIOTHERAPEUTICS TO WEBCAST CORPORATE PRESENTATION
AT THE 10TH ANNUAL BIO CEO & INVESTOR CONFERENCE
FRAMINGHAM, MA, February 6, 2008—GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., GTC’s Chairman and CEO, is scheduled to present on Wednesday, February 13, 2008 at 11:00 a.m. during the 10th Annual BIO CEO & Investor Conference. The conference is being held at the Waldorf=Astoria in New York, New York from February 11-13, 2008.
The presentation will be webcast live and can be accessed by logging onto
www.gtc-bio.com. The replay can be accessed from this same website and will be available within 24 hours of the presentation.
About GTC Biotherapeutics
GTC Biotherapeutics develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. In addition to ATryn®, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factor VIIa, factor VIII, factor IX, and alpha-1 antitrypsin. GTC also has a monoclonal antibody portfolio focused on follow-on biologics, including a CD20 monoclonal antibody. GTC’s intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC’s transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site,
www.gtc-bio.com. Nog maar enkele dagen goedkoop shoppen, dus.
P.